China Universal Asset Management Company’s Larimar Therapeutics LRMR Stock Holding History

China Universal Asset Management Company’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$86.7K	Buy	19,270 +5,323	+38%	+$21.3K	0.01%	420
2025 Q4	$53.1K	Sell	13,947 -1,056	-7%	-$4.11K	﹤0.01%	446
2025 Q3	$48.5K	Buy	15,003 +2,143	+17%	+$8.04K	﹤0.01%	433
2025 Q2	$37.2K	Buy	12,860 +61	+0.5%	+$141	﹤0.01%	435
2025 Q1	$27.5K	Sell	12,799 -730	-5%	-$2.31K	﹤0.01%	448
2024 Q4	$52.4K	Buy	+13,529	New	+$89.3K	﹤0.01%	449
2022 Q4	–	Sell	-165	Closed	-$1K	–	429
2022 Q3	$1K	Buy	+165	New	+$413	﹤0.01%	400

Other funds holding LRMR

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

China Universal Asset Management Company's LRMR Position: Q1 2026 in Review

China Universal Asset Management Company increased its Larimar Therapeutics (LRMR) stake by 38% in Q1 2026, buying an estimated $21.3K and bringing the position to 19,270 shares worth $86.7K. The position accounts for 0.01% of the portfolio, ranked #420.

China Universal Asset Management Company first reported a position in LRMR in Q3 2022 and has held it in 7 quarters since. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

China Universal Asset Management Company held 19,270 shares of Larimar Therapeutics worth $86.7K as of Q1 2026.
China Universal Asset Management Company bought 5,323 Larimar Therapeutics shares in Q1 2026, an estimated $21.3K.
Larimar Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q1 2026, its #420 holding.
China Universal Asset Management Company first reported a position in Larimar Therapeutics in Q3 2022 and has held it in 7 quarters since.
162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.